• to reduced the potential risk of severe cardiovascular (heart and blood vessel) challenges in Older people with style 2 diabetes and cardiovascular diseaseCalifornia biotech behemoth Amgen ditched strategies for an experimental weight loss tablet in May possibly but remains to be hoping for a slice of the market with MariTide, a monthly injecti